INVESTORS & MEDIA
News Release
Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the esophagus and prevents it from working properly, leading to difficulties swallowing and food impaction.[1] Food allergies are the main cause of eosinophilic esophagitis in a large number of patients. Corresponding with the increase in incidence of allergic diseases in the overall population, eosinophilic esophagitis is rapidly increasing in incidence.[2]
The primary endpoint of the study was the change from baseline to week 10 in the Straumann Dysphagia Instrument (SDI) score, a patient-reported measure of swallowing difficulty on a 0-9 point scale, with 9 indicating more severe symptoms. A total of 47 patients were randomized into two treatment groups in this 12-week treatment study, and both groups had a mean baseline SDI score of 6.4. Patients received either dupilumab 300 mg weekly following a 600 mg loading dose or placebo. At week 10, patients who received dupilumab 300 mg weekly reported a significant improvement in the ability to swallow with a three point reduction in their SDI score (45 percent improvement) compared to 1.3 points (19 percent improvement) for those patients who received placebo (p=0.0304).
Secondary endpoints of the study included measures of the impact of dupilumab on endoscopic and histopathologic measures of disease severity, as well as symptoms. The results include:
- The mean change in the Eosinophilic Esophagitis Endoscopic Reference Score (EoE-EREFS) was significantly reduced by 1.9 points from baseline (48 percent improvement) in patients who received dupilumab weekly compared to 0.3 points (7 percent improvement) for those who received placebo at 12 weeks (p=0.0006). EoE-EREFS is a visual measure of disease severity (inflammation and fibrosis in the esophagus) on a 0-8 point scale, with 8 indicating more severe disease. The mean baseline score for the dupilumab group was 3.9 and for the placebo group was 4.3.
- The mean percent change in overall peak intraepithelial eosinophil count from baseline to 12 weeks was significantly reduced by 93 percent from baseline in patients who received dupilumab weekly compared to an increase of 14 percent in those who received placebo (p < 0.0001).
- The mean percent change in a composite measure of symptoms and quality of life, as measured by Eosinophilic Esophagitis Symptom Activity Index (EEsAI), was numerically improved (although not statistically significant) by 35 percent in patients who received dupilumab weekly compared to an 11 percent improvement for those who received placebo at 10 weeks (p=0.085).
"Clinical manifestations of eosinophilic esophagitis in adults include difficulty swallowing and food impaction, which are consequences of pathological structural changes to the esophagus. Natural history studies have demonstrated an association between duration of untreated disease and the development of these esophageal changes," said Ikuo Hirano, M.D., Professor of Medicine,
There were no new significant safety concerns in this trial. Higher rates of injection site reactions were observed on dupilumab versus placebo.
Clinical and preclinical research indicates that the IL-4/IL-13 pathway may have an important role in allergic or Type 2 inflammation. Dupilumab, an antibody that inhibits IL-4/13 signaling, has been approved for moderate-to-severe atopic dermatitis in adults and has demonstrated clinical activity in other investigational areas under study (asthma and nasal polyps).
Eosinophilic esophagitis is a chronic disease characterized by high levels of eosinophils in the esophagus. The results of investigational IL-5 blocking studies in eosinophilic esophagitis suggest that eosinophils may act as a biomarker of broader allergic or Type 2 inflammation in the esophagus, but that eosinophils may not be solely responsible for disease activity. In the study presented today, the observed symptomatic and anatomic improvements associated with dupilumab, together with this reduction of eosinophils, suggest that dupilumab may have the potential to reverse multiple aspects of Type 2 inflammation in eosinophilic esophagitis.
Current treatment options for people with moderate-to-severe eosinophilic esophagitis are limited to diet modification, corticosteroids or surgery. The disease can affect patients' health-related quality of life, including altered eating behaviors and pain when swallowing. People with active, moderate-to-severe eosinophilic esophagitis live with the risk of complete blockage or injury to their esophagus because of food impaction, and emergency care is often required for severe obstructions.
Dupilumab recently received Orphan Drug Designation from the
The potential use of dupilumab in eosinophilic esophagitis is currently under clinical development and the safety and efficacy have not been fully evaluated by any regulatory authority.
About Dupilumab
Dupixent® (dupilumab) is the first and only biologic medicine
Dupilumab is a human monoclonal antibody that is designed to simultaneously inhibit overactive signaling of IL-4 and IL-13 cytokines, one of the root causes of Type 2 inflammation.
For more information on dupilumab clinical trials, please visit www.clinicaltrials.gov.
IMPORTANT SAFETY INFORMATION
Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.
Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:
- have eye problems
- have a parasitic (helminth) infection
- have asthma
- are scheduled to receive any vaccinations. You should not receive a "live vaccine" if you are treated with DUPIXENT.
- are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. If you have asthma and are taking asthma medicines, do not change or stop your asthma medicine without talking to your healthcare provider.
DUPIXENT can cause serious side effects, including:
- Allergic reactions. Stop using DUPIXENT and go to the nearest hospital emergency room if you get any of the following symptoms: fever, general ill feeling, swollen lymph nodes, hives, itching, joint pain, or skin rash.
- Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision.
The most common side effects include injection site reactions, eye and eyelid inflammation, including redness, swelling and itching, and cold sores in your mouth or on your lips.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-
Use DUPIXENT exactly as prescribed. If your healthcare provider decides that you or a caregiver can give DUPIXENT injections, you or your caregiver should receive training on the right way to prepare and inject DUPIXENT. Do not try to inject DUPIXENT until you have been shown the right way by your healthcare provider.
Please click here for the full Prescribing Information. The patient information is available here.
INDICATION
DUPIXENT is used to treat adult patients with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children. DUPIXENT is administered by subcutaneous injection every two weeks after an initial loading dose.
About
Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.
About
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six
Regeneron is accelerating and improving the traditional drug development process through its unique VelociSuite® technologies, including VelociGene® and VelocImmune®, and ambitious initiatives such as The Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although
Regeneron Forward-Looking Statements and Use of Digital Media
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
Contacts |
|
Media Relations |
Investor Relations |
|
|
Tel: +1 (908) 981 8745 |
Tel: +33 (0)1 53 77 45 45 |
Contacts Regeneron: |
|
Media Relations |
Investor Relations |
|
|
Tel: +1 (914) 847-3456 |
Tel: +1 (914) 847-5126 |
Mobile: +1 (914) 260-8788 |
|
[1]
[2] Wechsler, JB, Bryce, PJ. Allergic Mechanisms in Eosinophilic Esophagitis.
View original content:http://www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-positive-phase-2-study-results-for-dupilumab-in-patients-with-active-moderate-to-severe-eosinophilic-esophagitis-300536933.html
SOURCE
News Provided by Acquire Media